U.S. Pharma Stock News

For readers wondering whether Evercore's share price still offers value after a strong run, this article walks through what the current market price might be implying about the business. The stock last closed at US$374.02, with returns of 8.8% over 7 days, 12.8% over 30 days, 6.5% year to date and 37.8% over 1 year. The 3 year return is very large and the 5 year return is also very large. Recent coverage around Evercore has focused on its role as a major independent advisory firm and its...

If you are wondering whether Atlassian shares are offering fair value right now, you are not alone. This article will focus squarely on what the current price might mean for long term investors. The stock closed at US$158.36 recently, with returns of 2.3% year to date but a 36.1% decline over the past year, which raises questions about how the market is currently weighing its growth potential against risk. Recent attention on Atlassian has mainly centered on its collaboration and workflow...

In recent days, Fearnley Securities highlighted SFL Corporation’s bonds among its top picks, citing the company’s diversified exposure, solid charter backlog, and perceived credit strength. At the same time, SFL is drawing fresh interest from income-focused investors who value its long-term charter contracts, recurring cash flows, and emphasis on operational resilience over rapid growth. Next, we’ll examine how this renewed focus on SFL’s long-term cash flow stability and credit profile...

Recent analyst upgrades around Salesforce (CRM) and its agentic AI push have helped refocus attention on the stock, as investors weigh rising institutional interest against questions about how quickly new AI and data products scale. See our latest analysis for Salesforce. At a recent share price of US$262.90, Salesforce has seen a 9.35% 90 day share price return, while the 1 year total shareholder return of 18.56% decline contrasts with a 3 year total shareholder return of 80.48%. This...

In early January 2026, Perdoceo Education Corporation announced a new share repurchase program authorizing up to US$100 million of common stock buybacks through June 30, 2027, while confirming the prior plan had expired after repurchasing 2,500,000 shares for US$74.8 million. By pairing a fresh authorization with details of recent buybacks that retired nearly 3.9% of its shares, the company underscored an ongoing commitment to capital returns and balance sheet efficiency. Next, we’ll examine...

In recent days, Coinbase Global has received a Buy upgrade from Goldman Sachs and other upbeat analyst research, highlighting the company’s shift toward crypto infrastructure, subscription services, and a broader “everything exchange” model spanning crypto, equities, derivatives, and prediction markets. At the same time, Coinbase is pausing peso-to-USDC conversions and local banking rails in Argentina while continuing crypto-to-crypto trading, underscoring both its global expansion ambitions...

Dividend affirmation puts MetLife in focus for income investors MetLife (MET) is back on income investors’ radar after its board declared a first quarter 2026 common stock dividend of US$0.5675 per share, payable on March 10 to shareholders of record on February 3. See our latest analysis for MetLife. Recent trading has been relatively steady, with a 30 day share price return of 3.20% and a year to date share price return of 1.07%. The 5 year total shareholder return of 88.64% points to...

Why Campbell's (CPB) is catching investors' attention now Campbell's (CPB) has been under pressure, with the stock showing a 29% decline over the past year and weaker returns over the past 3 years and 5 years. At a last close of $27.01, Campbell's sits below its indicated intrinsic value estimate, with the data here pointing to a 55% intrinsic discount that may interest value focused investors. See our latest analysis for Campbell's. That picture of a 10.1% 1 month share price decline,...

If you are wondering whether Legend Biotech shares are pricing in too much hope or not enough, you are in the right place for a clear look at what you are actually paying for. The stock last closed at US$20.98, with returns of a 2.6% decline over 7 days, a 25.4% decline over 30 days, and a 37.5% decline over 1 year, which can change how investors think about both its growth potential and its risk. Recent coverage has focused on Legend Biotech's position in cell therapy, its partnerships with...

In late 2025, Interactive Brokers Group reported December metrics showing 3.384 million Daily Average Revenue Trades, client equity of US$779.9 billion, and client margin loan balances of US$90.2 billion, alongside a 32% year-over-year increase in accounts to 4.399 million. The company also disclosed that its individual and hedge fund clients, supported by low trading costs and global market access, collectively outperformed the S&P 500 Index in 2025, highlighting the platform’s role in...

Investors can buy low cost index fund if they want to receive the average market return. But if you invest in...

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...

The main aim of stock picking is to find the market-beating stocks. But the main game is to find enough winners to more...

Millicom International Cellular recently hit a 52-week high after reporting third-quarter 2025 earnings that surpassed Wall Street expectations and highlighted momentum from its acquisitions in Uruguay and Ecuador. This combination of earnings outperformance and expansion into new Latin American markets has sharpened investor focus on how Millicom is reshaping its regional footprint and growth profile. We’ll now examine how Millicom’s stronger-than-expected third-quarter earnings performance...

If you are wondering whether KB Home's current share price lines up with its underlying value, this article will walk you through the key signals to watch. The stock last closed at US$57.19, with returns of 0.4% over 7 days, a 9.7% decline over 30 days, a 0.2% gain year to date, and a 9.8% decline over 1 year, set against much stronger 3 year and 5 year returns of 71.7% and 80.9% respectively. These mixed returns can reflect shifting expectations around the housing market, interest rates,...

Zscaler, Inc. recently appointed Sunil Frida as Chief Marketing Officer to lead global marketing, brand strategy, and go-to-market execution across its Zero Trust and AI security portfolio. Frida’s background at CrowdStrike, Amazon Web Services, and General Electric may help Zscaler sharpen its messaging as AI-driven cyber threats gain urgency. Next, we’ll examine how this senior marketing hire could influence Zscaler’s long-term Zero Trust growth narrative and competitive positioning. These...

In December 2025, American Electric Power Company entered a Board Observer Agreement with the Icahn Group, granting Andrew J. Teno a non-voting observer role and imposing mutual standstill and non-disparagement restrictions that either side can terminate with notice. At the same time, fresh analyst coverage emphasized AEP’s earnings outlook tied to regulated investments and rising power demand, sharpening investor focus on how these trends could influence the company’s longer-term growth...

Corpay (CPAY) has drawn fresh attention after reporting third quarter 2025 results that exceeded analyst expectations on both earnings and revenue, alongside a multimillion dollar insider share purchase by director Steven T. Stull. See our latest analysis for Corpay. The recent earnings beat and insider buying come after a period where momentum has cooled, with a 1-year total shareholder return of an 8.63% decline even as the 3-year total shareholder return of 65.49% points to a much stronger...

If you are asking whether Tempus AI is priced attractively or already baking in a lot of optimism, the rest of this article is built to help you assess that question clearly. Tempus AI shares last closed at US$69.54, with returns of 15.2% over the past 7 days, an 11.5% gain year to date and a 78.9% return over the last year. The 30 day return sits at a 9.3% decline. Recent attention on Tempus AI has centered on its position in applying AI tools to healthcare data and its potential role in...

Fluence Energy (FLNC) has moved sharply into focus after its shares climbed more than 16% following upbeat guidance and supportive analyst commentary related to artificial intelligence driven power demand and grid modernization trends. See our latest analysis for Fluence Energy. That sharp move higher comes after a choppy stretch where the share price return is down 5.13% year to date but up 45.92% over 90 days, while the 1 year total shareholder return of 23.61% hints that recent momentum...

Recent analyst commentary on Matson (NYSE:MATX) has focused on slower revenue growth versus transportation peers, reduced free cash flow margins, and concerns about returns on capital, coinciding with a sharp move in the share price. See our latest analysis for Matson. The recent jump to a share price of $129.21 follows a 90 day share price return of 32.56% and a 30 day share price return of 11.01%. Over a longer horizon, the 1 year total shareholder return is a 5.49% decline and the 3 year...

Cincinnati Financial (CINF) has recently drawn attention after a mixed set of return figures, with the stock roughly flat over the month but showing a negative move across the past 3 months. See our latest analysis for Cincinnati Financial. At the current share price of $162.12, Cincinnati Financial’s recent 3 month share price return of a 2.07% decline contrasts with a 1 year total shareholder return of 16.55% and 5 year total shareholder return of 98.38%. This suggests that longer term...

Applied Optoelectronics recently reported its first volume order for 800G data-center transceivers from a major hyperscale customer and unveiled a 400-milliwatt pump laser for silicon photonics and co-packaged optics, with volume production targeted later in 2026. These developments highlight how Applied Optoelectronics is positioning its product lineup around higher-speed AI data-center infrastructure, where execution on volume shipments and manufacturing scale will be closely watched. We...

Recent performance snapshot for ACADIA Pharmaceuticals ACADIA Pharmaceuticals (ACAD) has been active in the market recently, with the share price up 3% over the past day and modestly positive over the past week, even as the past month shows a small decline. See our latest analysis for ACADIA Pharmaceuticals. Looking beyond the latest move, ACADIA Pharmaceuticals shows a 26.42% 90 day share price return and a 54.92% 1 year total shareholder return. Together, these figures indicate that...